RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease

  • Autoimmune Disorder
  • Crohn's Disease
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Cities
  • Boston
  • Chesterfield
  • Dothan
  • Hamden
  • Kissimmee
  • Nantes
  • Neuilly-sur-Seine
  • Roeselare
  • Szczecin
  • Vandœuvre-lès-Nancy
  • Warsaw
Trial Identifier:

NCT05910528 2023-504265-23-00 GA45392

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RVT-3101) in adult participants with moderate to severe active Crohn's disease.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT05910528, GA45392, 2023-504265-23-00 Trial Identifier
      RVT-3101 Treatments
      Crohns Disease Condition
      Official Title

      A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease

      Eligibility Criteria

      gender
      All Gender
      age
      ≥18 Years & ≤ 75 Years Age
      healthy-volunteers
      No Healthy Volunteers
      Inclusion Criteria
      • Moderately to severely active CD as defined by CDAI and SES-CD, assessed by central read
      • Elevated very soft or liquid stool frequency and/or abdominal pain
      • Must have no response, insufficient response, loss of response and/or intolerance to at least 1 conventional therapy (e.g. corticosteroids) or advanced therapy
      Exclusion Criteria
      • Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis or active diverticular disease
      • Short gut syndrome
      • Presence of an ostomy or ileoanal pouch
      • Bowel resection or diversion with ~6-months

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Crohn's Disease

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now